Cargando…

Histone Deacetylase Inhibitors and Microtubule Inhibitors Induce Apoptosis in Feline Luminal Mammary Carcinoma Cells

SIMPLE SUMMARY: Feline mammary tumors (FMT) are very common in cats, associated with very aggressive behavior and a short life expectancy. Surgery is the most used treatment but tumor recurrence is common. Currently, available therapies are insufficient, therefore, new molecular targets are needed t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Almeida, Filipe, Gameiro, Andreia, Correia, Jorge, Ferreira, Fernando
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918990/ https://www.ncbi.nlm.nih.gov/pubmed/33671894 http://dx.doi.org/10.3390/ani11020502

Ejemplares similares

Tyrosine Kinase Inhibitors Are Promising Therapeutic Tools for Cats with HER2-Positive Mammary Carcinoma
por: Gameiro, Andreia, et al.
Publicado: (2021)

VISTA Is a Diagnostic Biomarker and Immunotherapy Target of Aggressive Feline Mammary Carcinoma Subtypes
por: Gameiro, Andreia, et al.
Publicado: (2021)

Diagnostic Value of VEGF-A, VEGFR-1 and VEGFR-2 in Feline Mammary Carcinoma
por: Nascimento, Catarina, et al.
Publicado: (2021)

The Landscape of Tumor-Infiltrating Immune Cells in Feline Mammary Carcinoma: Pathological and Clinical Implications
por: Nascimento, Catarina, et al.
Publicado: (2022)

Emerging Biomarkers and Targeted Therapies in Feline Mammary Carcinoma
por: Gameiro, Andreia, et al.
Publicado: (2021)

HER2-Targeted Immunotherapy and Combined Protocols Showed Promising Antiproliferative Effects in Feline Mammary Carcinoma Cell-Based Models
por: Gameiro, Andreia, et al.
Publicado: (2021)

Serum and Tissue Expression Levels of Leptin and Leptin Receptor Are Putative Markers of Specific Feline Mammary Carcinoma Subtypes
por: Gameiro, Andreia, et al.
Publicado: (2021)

HER2-positive feline mammary carcinoma
por: Marques, Cláudia, et al.
Publicado: (2016)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

CXCR4 and its ligand CXCL12 display opposite expression profiles in feline mammary metastatic disease, with the exception of HER2-overexpressing tumors
por: Marques, Cláudia S., et al.
Publicado: (2018)

Serum PD-1/PD-L1 Levels, Tumor Expression and PD-L1 Somatic Mutations in HER2-Positive and Triple Negative Normal-Like Feline Mammary Carcinoma Subtypes
por: Nascimento, Catarina, et al.
Publicado: (2020)

Gene expression association study in feline mammary carcinomas
por: Ferreira, Daniela, et al.
Publicado: (2019)

Getting a GRP on histone deacetylase inhibitor selectivity
por: Ding, Husheng, et al.
Publicado: (2017)

Histone deacetylase inhibitors induce apoptosis in human eosinophils and neutrophils
por: Kankaanranta, Hannu, et al.
Publicado: (2010)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

TIM-3 Is a Potential Immune Checkpoint Target in Cats with Mammary Carcinoma
por: Valente, Sofia, et al.
Publicado: (2023)

Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy
por: Stankov, Metodi V., et al.
Publicado: (2013)

NOXA Accentuates Apoptosis Induction by a Novel Histone Deacetylase Inhibitor
por: Ashry, Ramy, et al.
Publicado: (2023)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Histone deacetylase inhibitors in multiple myeloma
por: Deleu, Sarah, et al.
Publicado: (2009)

Histone deacetylase inhibitors in Hodgkin lymphoma
por: Buglio, Daniela, et al.
Publicado: (2010)

Clinical Toxicities of Histone Deacetylase Inhibitors
por: Subramanian, Srividya, et al.
Publicado: (2010)

Acetylation and Histone Deacetylase Inhibitors in Cancer
por: Kortenhorst, Madeleine S. Q., et al.
Publicado: (2006)

Histone Deacetylase Inhibitors as Anticancer Drugs
por: Eckschlager, Tomas, et al.
Publicado: (2017)

The application of histone deacetylases inhibitors in glioblastoma
por: Chen, Rui, et al.
Publicado: (2020)

Histone Deacetylases and Their Inhibitors in Cancer Epigenetics
por: Hassell, Kelly N.
Publicado: (2019)

Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer
por: Tanioka, Maki, et al.
Publicado: (2018)

Histone Deacetylase Inhibitors Sensitize TRAIL-Induced Apoptosis in Colon Cancer Cells
por: Zhang, Baojie, et al.
Publicado: (2019)

Histone deacetylase inhibitors as novel anticancer therapeutics
por: Walkinshaw, D.R., et al.
Publicado: (2008)

Regulation of Immune Responses by Histone Deacetylase Inhibitors
por: Licciardi, Paul V., et al.
Publicado: (2012)

Interpreting clinical assays for histone deacetylase inhibitors
por: Martinet, Nadine, et al.
Publicado: (2011)

Myelodysplastic Syndrome and Histone Deacetylase Inhibitors: “To Be or Not to Be Acetylated”?
por: Stintzing, Sebastian, et al.
Publicado: (2011)

Overview of Histone Deacetylase Inhibitors in Haematological Malignancies
por: Bishton, Mark J., et al.
Publicado: (2010)

Dual Inhibitors Against Topoisomerases and Histone Deacetylases
por: Seo, Young Ho
Publicado: (2015)

Attenuation of Choroidal Neovascularization by Histone Deacetylase Inhibitor
por: Chan, Nymph, et al.
Publicado: (2015)

Zinc binding groups for histone deacetylase inhibitors
por: Zhang, Lei, et al.
Publicado: (2018)

The effect of histone deacetylase inhibitors on AHSP expression
por: Okhovat, Mohammad Ali, et al.
Publicado: (2018)

Histone Deacetylase Inhibitors and Diabetic Kidney Disease
por: Hadden, Mitchell J., et al.
Publicado: (2018)

The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy
por: Li, Guo, et al.
Publicado: (2020)

Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy
por: Verza, Flávia Alves, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_t45qdanje05f593fm44fpcklof